Join
Live feed
·
PRReleasevia Quantisnow
Harrow Inc. logo

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

ByQuantisnow·Wall Street's wire, on your screen.
HROW· Harrow Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HROW (Harrow Inc.) and more on Quantisnow.